Design, synthesis, and in vitro biological evaluation of novel benzimidazole tethered allylidenehydrazinylmethylthiazole derivatives as potent inhibitors of Mycobacterium tuberculosis. Issue 1 (19th November 2018)

• Record Type: Journal Article
• Authors: Surineni, Goverdhan; Gao, Yamin; Hussain, Muzammal; Liu, Zhiyong; Lu, Zhili; Chhotaray, Chiranjibi; Islam, Md Mahmudul; Hameed, H. M. Adnan; Zhang, Tianyu
• Is Part Of: MedChemComm. Volume 10:Issue 1(2019)
• Page Start: 49
• Page End: 60
• Publication Date: 2018-11-19
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c8md00389k
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : Development of novel chemical probe for antitubercular lead optimization. Abstract : Tuberculosis (TB) has become one of the most significant public health problems in recent years. Antibiotic therapy remains the mainstay of TB control strategies, but the increasing resistance of mycobacterial species has heightened alarm, requiring the development of novel drugs in order to improve treatment outcomes. Here, as an effort to identify novel and effective antitubercular agents, we designed and synthesized a series of novel substituted benzimidazolallylidenehydrazinylmethylthiazole derivatives via a multi-component molecular hybridization approach with single molecular architecture. Our design strategy involved assembling the antitubercular pharmacophoric fragments benzimidazole, 2-aminothiazole and substituted α, β-unsaturated ketones via condensation reactions. All the newly synthesized compounds were fully characterized via NMR and mass spectral data and evaluated for in vitro biological activity against the H37Ra strain of Mycobacterium tuberculosis . From the biological evaluation data, we identified some effective compounds, of which8g and7e were the most active ones (both having MIC values of 2.5 μg mL −1 ). In addition, compound8g exhibited a lower cytotoxicity profile. We conceive that compound8g may serve as a chemical probe of interest for further lead optimization studies with the general aim of developing novel and effective antitubercular agents.